Breathing pattern and pulmonary gas exchange in elderly patients with and without left ventricular dysfunction - modification with exercise-based cardiac rehabilitation and prognostic value.

Abstract

Aims In elderly patients with and without left ventricular dysfunction (LVD) we compared ventilatory parameters from before to after exercise-based cardiac rehabilitation (exCR) and assessed their prognostic value for major adverse cardiovascular events (MACE). Methods and Results Patients aged ≥65 years with acute or chronic coronary syndromes (ACS, CCS) without cardiac surgery who participated in a multicentre study on effectiveness of exCR from seven European countries were included. Cardiopulmonary exercise testing (CPET) was performed before, at termination of exCR and at 12 months follow-up. Ventilation (VE), breathing frequency (BF), tidal volume (VT) and end-expiratory carbon dioxide pressure (PETCO2) were measured at rest, at first ventilatory threshold and peak exercise. In 818 patients, age was 72.5±5.4 years, 21.9% were women, 79.8% had ACS, and 151 (18%) had LVD. NYHA functional class was not different between LVD and noLVD (86% NYHA I in each group). Compared to noLVD, in LVD resting VE was increased 8%, resting BF 6%, peak VE, peak VT, and peak PETCO2 reduced by 6%, 8%, and 5%, respectively, and VE/VVCO2 slope increased by 11%. From before to after exCR, resting VE decreased and peak PETCO2 increased significantly more in LVD compared to noLVD. In LVD, higher resting BF, higher nadir VE/VCO2, and lower peak PETCO2 at baseline were associated with MACE Conclusions In elderly patients with ischemic LVD, exaggerated resting ventilation and impaired pulmonary gas exchange during exercise was related to worse outcomes. ExCR was associated with an improvement of abnormal breathing patterns and gas exchange parameters.

Competing Interest Statement

AWJvH reports grants from Medtronic, grants and personal fees from Astra Zeneca, outside the submitted work, UZ reports grants and personal fees from Astra Zeneca, Bayer, BMS, Novartis, and MSD, and personal fees from Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Trommsdorf, and Amgen, all outside the submitted work.

Clinical Trial

trialregister.nl (NTR5306)

Funding Statement

The study was funded by the European Union's Horizon 2020 research and innovation program under grant agreement number 634439 and by the Swiss State Secretariat for Education, Research and Innovation for the Swiss consortium partner.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

n.a.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Data may be available upon request.

留言 (0)

沒有登入
gif